Update of clinical application in ceftazidime–avibactam for multidrug-resistant Gram-negative bacteria infections

[1] Grundmann H(2017)Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study Lancet Infect Dis 17 153-163

[2] Glasner C(2019)Pseudomonas aeruginosageographic and temporal patterns of antimicrobial resistance in over 20 years from the SENTRY antimicrobial surveillance program, 1997–2016 Open Forum Infect Dis 6 S63-S68

[3] Albiger B(2016)Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014 Infect Control Hosp Epidemiol 37 1288-1301

[4] Aanensen D(2015)Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit J Infect 70 592-599

[5] Tomlinson C(2016)Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing enterobacteriaceae in seven Latin American Countries PLoS ONE 11 240-246

[6] Andrasević A(2017)Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience Pathogens Global Health. 111 629-661

[7] Shortridge D(2016)Klebsiella pneumoniae: going on the offense with a strong defense Microbiol Mol Biol Rev 80 541-558

[8] Gales A(2016)Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications BMJ (Clin Res ed). 352 203-359

[9] Streit J(2021)The impact of carbapenem resistance on mortality in patients with klebsiella pneumoniae bloodstream infection: an individual patient data meta-analysis of 1952 patients Infect Dis Therapy. 10 353-3169

[10] Huband M(2018)Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance PLoS ONE 13 3163-177

[1] Grundmann H(2017)Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study Lancet Infect Dis 17 153-163

[2] Glasner C(2019)Pseudomonas aeruginosageographic and temporal patterns of antimicrobial resistance in over 20 years from the SENTRY antimicrobial surveillance program, 1997–2016 Open Forum Infect Dis 6 S63-S68

[3] Albiger B(2016)Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014 Infect Control Hosp Epidemiol 37 1288-1301

[4] Aanensen D(2015)Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit J Infect 70 592-599

[5] Tomlinson C(2016)Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing enterobacteriaceae in seven Latin American Countries PLoS ONE 11 240-246

[6] Andrasević A(2017)Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience Pathogens Global Health. 111 629-661

[7] Shortridge D(2016)Klebsiella pneumoniae: going on the offense with a strong defense Microbiol Mol Biol Rev 80 541-558

[8] Gales A(2016)Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications BMJ (Clin Res ed). 352 203-359

[9] Streit J(2021)The impact of carbapenem resistance on mortality in patients with klebsiella pneumoniae bloodstream infection: an individual patient data meta-analysis of 1952 patients Infect Dis Therapy. 10 353-3169

[10] Huband M(2018)Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance PLoS ONE 13 3163-177